Provision of Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England Region

Concepts

• health services
• leeds
• england regionrespiratory syncytial virus
• community pharmacy respiratory syncytial virus
• england region
• nhe england
• greater east midlands commissioning support unit
• rsv
• provision of community pharmacy respiratory syncytial virus
• community pharmacy respiratory syncytial virus (rsv) vaccination

Location

Leeds

Description

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England RegionRespiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:• an adult programme (predominately to be commissioned through general practice); and• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts). This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient. The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029. Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024. NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU) on behalf of NHE England (NHSE) (The Commissioner) would like to notify the market of an opportunity to provide Community Pharmacy Respiratory Syncytial Virus (RSV) Vaccination within the East of England RegionRespiratory Syncytial Virus (RSV) is a virus that for most people causes a mild respiratory illness, but can be more serious for those, including older adults and infants, who are at risk of more severe respiratory disease. Following the Joint Committee on Vaccination and Immunisation (JCVI) recommendation, the Commissioner will commission from September 2024:• an adult programme (predominately to be commissioned through general practice); and• an infant programme provided as vaccination during pregnancy (predominantly to be commissioned through NHS Trusts).This Procurement Process is for the Early Adoption Phase in the East of England Region where up to 50 Potential Suppliers will be selected to provide the services. The 50 Successful Suppliers will be in 2 ICBs within the East of England Region to allow the Commissioner to ensure an even geographical spread. The ICB's included in this procurement are NHS Mid and South Essex ICB and Suffolk and North East Essex ICB.The value of the service provision resulting from this Procurement Process will be an Item of Service (IoS) fee of £9.58 for the administration of each RSV vaccine to each eligible patient.The number of eligible patients, and therefore the likely activity level, could change as a result of factors beyond the Commissioner’s control such as an increase or decrease in population of the local area, closure or merger of other nearby NHS health organisations, or patient.Services will commence in September 2024 and will continue until 31st March 2027, with an option for the Commissioner to extend for 24 months until 31 March 2029.The award criteria is as stated below:Integration, collaboration and service sustainability - 40.00%Improving access, reducing health inequalities and facilitating choice - 45.00%Quality and Innovation - 5.00%Social Value - 10.00%Value

Lot Division

CPV Codes

• 85100000 - Health services

Indicators

• Bids should cover exactly one lot.
• Bids should cover a maximum number of lots.
• Renewals are not available.
• Award on basis of price and quality.

Other Information

- Pass / FailPlease see published procurement documentation for further details. All relevant information on the stages of evaluation are stated within the ITT documentation suite.Please note the deadline for responses to the ITT is 12:00PM (Mid-Day) on 7th August 2024. This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The Contracting Authority will be using an eTendering system for this procurement exercise.Further information and the ITT documentation can be found via the 'Live Opportunities' list on the e-tendering system at the following link:https://health-family-contract-search.secure.force.com/?searchtype=ProjectsYou can also register your interest via this page. You can search for the opportunity by entering the following contract reference: C297044 - COMPETITIVE: RSV Community Pharmacy Pathfinder ServiceNeither the publication of this notice nor the employment of any particular terminology nor any other indication shall be taken to mean that the Contracting Authority intends to hold itself bound by any of the Regulations.The award criteria is as stated below:Integration, collaboration and service sustainability … All relevant information on the stages of evaluation are stated within the ITT documentation suite.